{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T04:01:55Z","timestamp":1791950515256,"version":"4.3.4"},"reference-count":100,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Mucous membrane pemphigoid (MMP) is considered an autoimmune blistering disease that predominantly affects mucous membranes. Various treatments are available for controlling the diseases, but not all of them may respond.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>PubMed and Google Scholar were searched for all the associated studies until 2015, using the keywords such as \u201ccicatricial pemphigoid\u201d or \u201cocular pemphigoid\u201d or \u201cmucous membrane pemphigoid\u201d or \u201cMMP\u201d and \u201cintravenous immunoglobulin\u201d or \u201cIVIg\u201d to find all the relevant studies. The last search update was for September 2, 2015. Among the searched items, only English studies were included in the review.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>After excluding nonrelevant studies, 13 studies with a total number of seventy patients with MMP who were under treatment with IVIg were analyzed. The 65 patients responded completely, one did not respond, two had partially responded, and the remaining two patients stopped IVIg therapy, which resulted in ocular cicatricial pemphigoid progression. Majority of the studies reported mild adverse effects while two of them did not report any unwanted side effect. The most common side effect was headache, followed by nausea. Most of the patients who had a cessation of IVIg therapy before achieving clinical remission experienced the disease progression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Overall, it can be concluded that IVIg therapy was very helpful in treatment of MMP patients who did not respond to conventional therapy or stopped using them for various side effects. Adverse effects associated with IVIg therapy were considerably lower than conventional therapy that can lead toward treatment with this agent in patients who suffer from severe side effects.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/1735-1995.183992","type":"journal-article","created":{"date-parts":[[2016,6,14]],"date-time":"2016-06-14T05:01:03Z","timestamp":1465880463000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":16,"title":["The role of intravenous immunoglobulin in treatment of mucous membrane pemphigoid: A review of literature"],"prefix":"10.4103","volume":"21","author":[{"given":"Soheil","family":"Tavakolpour","sequence":"first","affiliation":[{"name":"Department of Dermatology, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran"},{"name":"Skin Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2016,6,14]]},"reference":[{"key":"R1-20250827","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2174\/15665240113136660079","article-title":"Molecular diagnosis in autoimmune skin blistering conditions","volume":"14","author":"Otten","year":"2014","journal-title":"Curr Mol Med"},{"key":"R2-20250827","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1067\/mjd.2000.107248","article-title":"Cicatricial pemphigoid","volume":"43","author":"Fleming","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"R3-20250827","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2340\/00015555-0083","article-title":"Childhood oral mucous membrane pemphigoid presenting as desquamative gingivitis in a 4-year-old girl","volume":"86","author":"Louren\u00e7o","year":"2006","journal-title":"Acta Derm Venereol"},{"key":"R4-20250827","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1097\/ICO.0b013e3182a0ce6e","article-title":"Childhood mucous membrane pemphigoid: A case with exclusively ocular involvement","volume":"32","author":"Lavall\u00e9e","year":"2013","journal-title":"Cornea"},{"key":"R5-20250827","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/1523-1747.ep12480369","article-title":"The subclass distribution of IgG autoantibodies in cicatricial pemphigoid and epidermolysis bullosa acquisita","volume":"97","author":"Bernard","year":"1991","journal-title":"J Invest Dermatol"},{"key":"R6-20250827","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/1523-1747.ep12337073","article-title":"Noncomplement fixing, IgG4 autoantibodies predominate in patients with anti-epiligrin cicatricial pemphigoid","volume":"109","author":"Hsu","year":"1997","journal-title":"J Invest Dermatol"},{"key":"R7-20250827","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/01.md.0000076003.64510.00","article-title":"Anti-epiligrin cicatricial pemphigoid: Clinical findings, immunopathogenesis, and significant associations","volume":"82","author":"Egan","year":"2003","journal-title":"Medicine (Baltimore)"},{"key":"R8-20250827","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ophtha.2003.03.001","article-title":"Mucous membrane pemphigoid and pseudopemphigoid","volume":"111","author":"Thorne","year":"2004","journal-title":"Ophthalmology"},{"key":"R9-20250827","doi-asserted-by":"crossref","first-page":"617","DOI":"10.2147\/TCRM.S1140","article-title":"Treatment strategies in mucous membrane pemphigoid","volume":"4","author":"Neff","year":"2008","journal-title":"Ther Clin Risk Manag"},{"key":"R10-20250827","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1529-8019.2010.01323.x","article-title":"The management of mucous membrane pemphigoid and pemphigus","volume":"23","author":"Knudson","year":"2010","journal-title":"Dermatol Ther"},{"key":"R11-20250827","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/bjd.12041","article-title":"Oral cyclophosphamide without corticosteroids to treat mucous membrane pemphigoid","volume":"168","author":"Munyangango","year":"2013","journal-title":"Br J Dermatol"},{"key":"R12-20250827","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0161-6420(01)00863-6","article-title":"The effect of treatment and its related side effects in patients with severe ocular cicatricial pemphigoid","volume":"109","author":"Miserocchi","year":"2002","journal-title":"Ophthalmology"},{"key":"R13-20250827","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1046\/j.1529-8019.2002.01539.x","article-title":"Inhibitors of purine and pyrimidine synthesis: Mycophenolate, azathioprine, and leflunomide","volume":"15","author":"Mimouni","year":"2002","journal-title":"Dermatol Ther"},{"key":"R14-20250827","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1097\/ICO.0b013e31826af7b8","article-title":"Treatment of mucous membrane pemphigoid with mycophenolate mofetil","volume":"32","author":"Nottage","year":"2013","journal-title":"Cornea"},{"key":"R15-20250827","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1067\/mjd.2001.114746","article-title":"Treatment of cicatricial pemphigoid with mycophenolate mofetil as a steroid-sparing agent","volume":"45","author":"Megahed","year":"2001","journal-title":"J Am Acad Dermatol"},{"key":"R16-20250827","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.ophtha.2003.07.010","article-title":"Methotrexate therapy for ocular cicatricial pemphigoid","volume":"111","author":"McCluskey","year":"2004","journal-title":"Ophthalmology"},{"key":"R17-20250827","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.oftal.2013.10.009","article-title":"Methotrexate as a treatment in ocular cicatricial moderate pemphigoid","volume":"89","author":"Herv\u00e1s Ontiveros","year":"2014","journal-title":"Arch Soc Esp Oftalmol"},{"key":"R18-20250827","doi-asserted-by":"crossref","first-page":"e49","DOI":"10.1016\/j.oooo.2012.01.030","article-title":"Treatment of mucous membrane pemphigoid with the combination of mycophenolate mofetil, dapsone, and prednisolone: A case series","volume":"114","author":"Staines","year":"2012","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"R19-20250827","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/j.1600-0714.2008.00653.x","article-title":"The management of oral mucous membrane pemphigoid with dapsone and topical corticosteroid","volume":"37","author":"Arash","year":"2008","journal-title":"J Oral Pathol Med"},{"key":"R20-20250827","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1001\/archdermatol.2011.54","article-title":"Rituximab for patients with refractory mucous membrane pemphigoid","volume":"147","author":"Le Roux-Villet","year":"2011","journal-title":"Arch Dermatol"},{"key":"R21-20250827","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.jaad.2013.01.046","article-title":"Treatment of mucous membrane pemphigoid with rituximab","volume":"69","author":"Heelan","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"R22-20250827","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1038\/sj.eye.6702948","article-title":"Successful biologic treatment of ocular mucous membrane pemphigoid with anti-TNF-alpha","volume":"21","author":"John","year":"2007","journal-title":"Eye (Lond)"},{"key":"R23-20250827","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1067\/mjd.2001.119100","article-title":"Treatment of recalcitrant cicatricial pemphigoid with the tumor necrosis factor alpha antagonist etanercept","volume":"46","author":"Sacher","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"R24-20250827","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1001\/archderm.142.11.1457","article-title":"Successful treatment of mucous membrane pemphigoid with etanercept in 3 patients","volume":"142","author":"Canizares","year":"2006","journal-title":"Arch Dermatol"},{"key":"R25-20250827","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1001\/archderm.142.10.1268","article-title":"Successful treatment of mucous membrane pemphigoid with infliximab","volume":"142","author":"Heffernan","year":"2006","journal-title":"Arch Dermatol"},{"issue":"1 Suppl 2","key":"R26-20250827","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1053\/sonc.2002.30156","article-title":"Rituximab: Mechanism of action and resistance","volume":"29","author":"Maloney","year":"2002","journal-title":"Semin Oncol"},{"issue":"5 Suppl 14","key":"R27-20250827","first-page":"66","article-title":"Overview of the clinical development of rituximab: First monoclonal antibody approved for the treatment of lymphoma","volume":"26","author":"Grillo-L\u00f3pez","year":"1999","journal-title":"Semin Oncol"},{"key":"R28-20250827","first-page":"269","article-title":"Rituximab for autoimmune blistering diseases: Recent studies, new insights","volume":"147","author":"Lunardon","year":"2012","journal-title":"G Ital Dermatol Venereol"},{"issue":"Suppl 3","key":"R29-20250827","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00415-008-3002-0","article-title":"Advances in the understanding of the mechanism of action of IVIg","volume":"255","author":"Hartung","year":"2008","journal-title":"J Neurol"},{"key":"R30-20250827","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1385\/CRIAI:29:3:173","article-title":"Intravenous immunoglobulin: Adverse effects and safe administration","volume":"29","author":"Orbach","year":"2005","journal-title":"Clin Rev Allergy Immunol"},{"key":"R31-20250827","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1136\/adc.2005.078733","article-title":"A prospective study of the immediate and delayed adverse events following intravenous immunoglobulin infusions","volume":"91","author":"Singh-Grewal","year":"2006","journal-title":"Arch Dis Child"},{"key":"R32-20250827","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/j.1365-2133.1997.tb03770.x","article-title":"Cicatricial pemphigoid treated with intravenous immunoglobulin","volume":"137","author":"Urcelay","year":"1997","journal-title":"Br J Dermatol"},{"key":"R33-20250827","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1016\/S0161-6420(99)90496-7","article-title":"Intravenous immunoglobulin therapy for ocular cicatricial pemphigoid: A preliminary study","volume":"106","author":"Foster","year":"1999","journal-title":"Ophthalmology"},{"key":"R34-20250827","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1001\/archderm.137.9.1181","article-title":"Comparison between intravenous immunoglobulin and conventional immunosuppressive therapy regimens in patients with severe oral pemphigoid: Effects on disease progression in patients nonresponsive to dapsone therapy","volume":"137","author":"Ahmed","year":"2001","journal-title":"Arch Dermatol"},{"key":"R35-20250827","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1067\/mjd.2002.117860","article-title":"Cicatricial pemphigoid with circulating IgA and IgG autoantibodies to the central portion of the BP180 ectodomain: Beneficial effect of adjuvant therapy with high-dose intravenous immunoglobulin","volume":"46","author":"Leverkus","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"R36-20250827","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1006\/clim.2001.5150","article-title":"Intravenous immunoglobulin therapy in patients with multiple mucosal involvement in mucous membrane pemphigoid","volume":"102","author":"Sami","year":"2002","journal-title":"Clin Immunol"},{"key":"R37-20250827","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.clim.2003.11.002","article-title":"A nonrandomized comparison of the clinical outcome of ocular involvement in patients with mucous membrane (cicatricial) pemphigoid between conventional immunosuppressive and intravenous immunoglobulin therapies","volume":"111","author":"Letko","year":"2004","journal-title":"Clin Immunol"},{"key":"R38-20250827","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/j.ophtha.2003.11.012","article-title":"Intravenous immunoglobulin therapy in patients with ocular-cicatricial pemphigoid: A long-term follow-up","volume":"111","author":"Sami","year":"2004","journal-title":"Ophthalmology"},{"key":"R39-20250827","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.jaad.2006.06.029","article-title":"High-dose intravenous immunoglobulins for the treatment of autoimmune mucocutaneous blistering diseases: Evaluation of its use in 19 cases","volume":"56","author":"Segura","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"R40-20250827","doi-asserted-by":"crossref","first-page":"752.e1","DOI":"10.1016\/j.ophtha.2007.10.029","article-title":"Intravenous immunoglobulins and mucous membrane pemphigoid","volume":"115","author":"Mignogna","year":"2008","journal-title":"Ophthalmology"},{"key":"R41-20250827","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1097\/ICO.0b013e318172fbc5","article-title":"Intravenous immunoglobulin therapy for refractory ocular cicatricial pemphigoid: Case report","volume":"27","author":"Galdos","year":"2008","journal-title":"Cornea"},{"key":"R42-20250827","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1365-2230.2008.02809.x","article-title":"Analysis of thromboembolic risk related to high-dose intravenous immunoglobulin treatment: A preliminary clinical study of 10 patients with autoimmune mucocutaneous blistering diseases","volume":"34","author":"Mignogna","year":"2009","journal-title":"Clin Exp Dermatol"},{"key":"R43-20250827","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.ophtha.2009.09.049","article-title":"Combination of rituximab and intravenous immunoglobulin for recalcitrant ocular cicatricial pemphigoid: A preliminary report","volume":"117","author":"Foster","year":"2010","journal-title":"Ophthalmology"},{"key":"R44-20250827","first-page":"565","article-title":"Mucous membrane pemphigoid with severe esophageal stricture","volume":"86","author":"Barbosa Ldo","year":"2011","journal-title":"An Bras Dermatol"},{"key":"R45-20250827","first-page":"930859","article-title":"Unilateral oral mucous membrane pemphigoid: Refractory atypical presentation successfully treated with intravenous immunoglobulins","author":"Laureano","year":"2015","journal-title":"Case Rep Dermatol Med 2015"},{"key":"R46-20250827","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1001\/archderm.139.8.1051","article-title":"Consensus statement on the use of intravenous immunoglobulin therapy in the treatment of autoimmune mucocutaneous blistering diseases","volume":"139","author":"Ahmed","year":"2003","journal-title":"Arch Dermatol"},{"key":"R47-20250827","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.cyto.2015.09.017","article-title":"Interleukin 4 inhibition as a potential therapeutic in pemphigus","volume":"77","author":"Tavakolpour","year":"2016","journal-title":"Cytokine"},{"key":"R48-20250827","doi-asserted-by":"crossref","DOI":"10.1111\/dth.12327","article-title":"Dupilumab: A revolutionary emerging drug in atopic dermatitis and its possible role in pemphigus","author":"Tavakolpour","year":"2016","journal-title":"Dermatol Ther"},{"key":"R49-20250827","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1056\/NEJMra993360","article-title":"Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin","volume":"345","author":"Mackay","year":"2001","journal-title":"N Engl J Med"},{"key":"R50-20250827","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1111\/j.1468-1331.2008.02258.x","article-title":"Treatment of corticosteroid refractory optic neuritis in multiple sclerosis patients with intravenous immunoglobulin","volume":"15","author":"Tselis","year":"2008","journal-title":"Eur J Neurol"},{"key":"R51-20250827","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1177\/135245859700300214","article-title":"Treatment effects of monthly intravenous immunoglobulin on patients with relapsing-remitting multiple sclerosis: Further analyses of the Austrian Immunoglobulin in MS study","volume":"3","author":"Fazekas","year":"1997","journal-title":"Mult Scler"},{"key":"R52-20250827","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1191\/1352458504ms1079sr","article-title":"Intravenous corticosteroids in the postpartum period for reduction of acute exacerbations in multiple sclerosis","volume":"10","author":"de Seze","year":"2004","journal-title":"Mult Scler"},{"key":"R53-20250827","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1001\/archneur.61.10.1515","article-title":"Intravenous immunoglobulin treatment following the first demyelinating event suggestive of multiple sclerosis: A randomized, double-blind, placebo-controlled trial","volume":"61","author":"Achiron","year":"2004","journal-title":"Arch Neurol"},{"key":"R54-20250827","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S0140-6736(96)09377-4","article-title":"Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group","volume":"349","author":"Fazekas","year":"1997","journal-title":"Lancet"},{"key":"R55-20250827","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1212\/01.wnl.0000318281.98220.6f","article-title":"Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: A dose-finding trial","volume":"71","author":"Fazekas","year":"2008","journal-title":"Neurology"},{"key":"R56-20250827","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(04)17101-8","article-title":"Intravenous immunoglobulin in secondary progressive multiple sclerosis: Randomised placebo-controlled trial","volume":"364","author":"Hommes","year":"2004","journal-title":"Lancet"},{"key":"R57-20250827","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1212\/WNL.50.2.398","article-title":"Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses","volume":"50","author":"Achiron","year":"1998","journal-title":"Neurology"},{"key":"R58-20250827","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1191\/096120399678841007","article-title":"A study of 20 SLE patients with intravenous immunoglobulin \u2013 Clinical and serologic response","volume":"8","author":"Levy","year":"1999","journal-title":"Lupus"},{"key":"R59-20250827","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1007\/s100670050079","article-title":"Successful treatment of systemic lupus erythematosus cerebritis with intravenous immunoglobulin","volume":"18","author":"Sherer","year":"1999","journal-title":"Clin Rheumatol"},{"key":"R60-20250827","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1681\/ASN.V5101746","article-title":"Intravenous immune globulin in the treatment of patients with systemic lupus erythematosus and end-stage renal disease","volume":"5","author":"Becker","year":"1995","journal-title":"J Am Soc Nephrol"},{"key":"R61-20250827","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1093\/rheumatology\/ken046","article-title":"Intravenous immunoglobulin therapy in pregnant patients affected with systemic lupus erythematosus and recurrent spontaneous abortion","volume":"47","author":"Perricone","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"R62-20250827","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1002\/art.1780330825","article-title":"Intravenous immunoglobulin therapy in systemic lupus erythematosus-associated thrombocytopenia","volume":"33","author":"Maier","year":"1990","journal-title":"Arthritis Rheum"},{"key":"R63-20250827","first-page":"71","article-title":"High dose intravenous immunoglobulins in systemic lupus erythematosus: Clinical and serological results of a pilot study","volume":"23","author":"Schroeder","year":"1996","journal-title":"J Rheumatol"},{"key":"R64-20250827","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1136\/ard.54.5.382","article-title":"Long term treatment of rheumatoid arthritis with high doses of intravenous immunoglobulins: Effects on disease activity and serum cytokines","volume":"54","author":"Muscat","year":"1995","journal-title":"Ann Rheum Dis"},{"key":"R65-20250827","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1002\/art.1780351004","article-title":"High-dose immunoglobulin therapy as an immunomodulatory treatment of rheumatoid arthritis","volume":"35","author":"Tumiati","year":"1992","journal-title":"Arthritis Rheum"},{"key":"R66-20250827","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1002\/art.1780390621","article-title":"Failure of low-dose intravenous immunoglobulin therapy to suppress disease activity in patients with treatment-refractory rheumatoid arthritis","volume":"39","author":"Kanik","year":"1996","journal-title":"Arthritis Rheum"},{"key":"R67-20250827","first-page":"657","article-title":"High dose intravenous immunoglobulin (IVIg) in severe refractory rheumatoid arthritis: No evidence for efficacy","volume":"14","author":"Maksymowych","year":"1996","journal-title":"Clin Exp Rheumatol"},{"key":"R68-20250827","first-page":"2353","article-title":"Intravenous immunoglobulin in the treatment of systemic juvenile rheumatoid arthritis: A randomized placebo controlled trial. Pediatric Rheumatology Collaborative Study Group","volume":"21","author":"Silverman","year":"1994","journal-title":"J Rheumatol"},{"key":"R69-20250827","first-page":"919","article-title":"Intravenous immunoglobulin in the treatment of polyarticular juvenile rheumatoid arthritis: A phase I\/II study. Pediatric Rheumatology Collaborative Study Group","volume":"23","author":"Giannini","year":"1996","journal-title":"J Rheumatol"},{"key":"R70-20250827","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1007\/BF01892896","article-title":"Immunomodulating therapy of rheumatoid arthritis by high-dose intravenous immunoglobulin","volume":"67","author":"Becker","year":"1989","journal-title":"Klin Wochenschr"},{"key":"R71-20250827","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/0002-9343(88)90106-4","article-title":"Rapid transient reversal of anemia and long-term effects of maintenance intravenous immunoglobulin for autoimmune hemolytic anemia in patients with lymphoproliferative disorders","volume":"84","author":"Besa","year":"1988","journal-title":"Am J Med"},{"key":"R72-20250827","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/j.1600-0609.1985.tb00767.x","article-title":"Lack of efficacy of high-dose intravenous immunoglobulin in autoimmune haemolytic anaemia: A clue to its mechanism","volume":"34","author":"Mueller-Eckhardt","year":"1985","journal-title":"Scand J Haematol"},{"key":"R73-20250827","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/ajh.2830440404","article-title":"Efficacy of intravenous immunoglobulin in the treatment of autoimmune hemolytic anemia: Results in 73 patients","volume":"44","author":"Flores","year":"1993","journal-title":"Am J Hematol"},{"key":"R74-20250827","first-page":"264","article-title":"Intravenous treatment of autoimmune hemolytic anemia with very high dose gammaglobulin","volume":"51","author":"Bussel","year":"1986","journal-title":"Vox Sang"},{"key":"R75-20250827","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1365-2257.1988.tb01186.x","article-title":"High-dose intravenous immunoglobulin in the treatment of autoimmune haemolytic anaemia","volume":"10","author":"Majer","year":"1988","journal-title":"Clin Lab Haematol"},{"issue":"2 Pt 2","key":"R77-20250827","doi-asserted-by":"crossref","first-page":"S156","DOI":"10.1016\/0090-1229(89)90081-0","article-title":"Immunomodulatory effects of intravenous immunoglobulin in severe steroid-dependent asthma","volume":"53","author":"Mazer","year":"1989","journal-title":"Clin Immunol Immunopathol"},{"key":"R78-20250827","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1136\/thx.52.7.662","article-title":"Effects of high dose intravenous immunoglobulin in two severe corticosteroid insensitive asthmatic patients","volume":"52","author":"Vrugt","year":"1997","journal-title":"Thorax"},{"key":"R79-20250827","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1378\/chest.114.5.1349","article-title":"Benefits of high-dose i.v. immunoglobulin in patients with severe steroid-dependent asthma","volume":"114","author":"Landwehr","year":"1998","journal-title":"Chest"},{"key":"R80-20250827","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1046\/j.1365-2222.1998.00214.x","article-title":"Prospective, double-blind, placebo-controlled, multicentre study on the effect of high-dose, intravenous immunoglobulin in children and adolescents with severe bronchial asthma","volume":"28","author":"Niggemann","year":"1998","journal-title":"Clin Exp Allergy"},{"key":"R81-20250827","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1006\/clim.1999.4714","article-title":"A multicenter, randomized, double-blind, placebo-controlled trial of high-dose intravenous immunoglobulin for oral corticosteroid-dependent asthma","volume":"91","author":"Kishiyama","year":"1999","journal-title":"Clin Immunol"},{"key":"R82-20250827","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1067\/mjd.2001.116339","article-title":"Intravenous immunoglobulin therapy in the treatment of patients with pemphigus vulgaris unresponsive to conventional immunosuppressive treatment","volume":"45","author":"Ahmed","year":"2001","journal-title":"J Am Acad Dermatol"},{"key":"R83-20250827","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1111\/j.1468-3083.2006.01540.x","article-title":"The role of IVIg treatment in severe pemphigus vulgaris","volume":"20","author":"Baum","year":"2006","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R84-20250827","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1001\/archderm.138.9.1158","article-title":"Corticosteroid-sparing effect of intravenous immunoglobulin therapy in patients with pemphigus vulgaris","volume":"138","author":"Sami","year":"2002","journal-title":"Arch Dermatol"},{"key":"R85-20250827","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1067\/mjd.2002.122735","article-title":"Treatment of pemphigus with intravenous immunoglobulin","volume":"47","author":"Bystryn","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"R86-20250827","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1067\/mjd.2000.108366","article-title":"Analysis of current data on the use of intravenous immunoglobulins in management of pemphigus vulgaris","volume":"43","author":"Engineer","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"R87-20250827","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1111\/1346-8138.12280","article-title":"Four mild but refractory cases of pemphigus foliaceus successfully treated with intravenous immunoglobulin","volume":"40","author":"Kawakami","year":"2013","journal-title":"J Dermatol"},{"issue":"4 Suppl 1","key":"R88-20250827","doi-asserted-by":"crossref","first-page":"S133","DOI":"10.1590\/S0365-05962011000700035","article-title":"Refractory endemic pemphigus foliaceous in adolescence successfully treated with intravenous immunoglobulin","volume":"86","author":"Teixeira","year":"2011","journal-title":"An Bras Dermatol"},{"key":"R89-20250827","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1067\/mjd.2002.116338","article-title":"Intravenous immunoglobulin therapy for patients with pemphigus foliaceus unresponsive to conventional therapy","volume":"46","author":"Ahmed","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"R90-20250827","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1365-2230.2005.01989.x","article-title":"Epidermolysis bullosa acquisita: Diagnosis by fluorescence overlay antigen mapping and clinical response to high-dose intravenous immunoglobulin","volume":"31","author":"Campos","year":"2006","journal-title":"Clin Exp Dermatol"},{"key":"R91-20250827","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1111\/j.1468-3083.2011.04205.x","article-title":"Treatment of epidermolysis bullosa acquisita with intravenous immunoglobulin in patients non-responsive to conventional therapy: Clinical outcome and post-treatment long-term follow-up","volume":"26","author":"Ahmed","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2 Pt 2","key":"R92-20250827","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/0190-9622(93)70189-Z","article-title":"Epidermolysis bullosa acquisita: Efficacy of high-dose intravenous immunoglobulins","volume":"29","author":"Meier","year":"1993","journal-title":"J Am Acad Dermatol"},{"key":"R93-20250827","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.clim.2008.08.003","article-title":"Subcutaneous immunoglobulin therapy for immunomodulation in a patient with severe epidermolysis bullosa acquisita","volume":"129","author":"Tayal","year":"2008","journal-title":"Clin Immunol"},{"key":"R94-20250827","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.jaad.2007.08.005","article-title":"Infantile bullous pemphigoid treated with intravenous immunoglobulin therapy","volume":"57","author":"Sugawara","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"R95-20250827","first-page":"264","article-title":"Bullous pemphigoid treated with intravenous immunoglobulin","volume":"93","author":"Tuchinda","year":"2014","journal-title":"Cutis"},{"key":"R96-20250827","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1001\/jama.1992.03490040059026","article-title":"Prophylactic intravenous immunoglobulin in HIV-infected children with CD4+counts of 0.20\u00d710 (9)\/L or more. Effect on viral, opportunistic, and bacterial infections. The National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group","volume":"268","author":"Mofenson","year":"1992","journal-title":"JAMA"},{"key":"R97-20250827","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1742-6405-6-15","article-title":"Reduction of the HIV-1 reservoir in resting CD4+T-lymphocytes by high dosage intravenous immunoglobulin treatment: A proof-of-concept study","volume":"6","author":"Lindkvist","year":"2009","journal-title":"AIDS Res Ther"},{"issue":"2 Suppl","key":"R98-20250827","doi-asserted-by":"crossref","first-page":"42S","DOI":"10.1007\/BF00918366","article-title":"Use of intravenous immune globulin in patients receiving bone marrow transplants","volume":"2","author":"Winston","year":"1982","journal-title":"J Clin Immunol"},{"key":"R99-20250827","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1128\/AAC.31.12.1882","article-title":"Intravenous immunoglobulin treatment of respiratory syncytial virus infections in infants and young children","volume":"31","author":"Hemming","year":"1987","journal-title":"Antimicrob Agents Chemother"},{"key":"R100-20250827","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1086\/342412","article-title":"Immune-globulin prophylaxis of respiratory syncytial virus infection in patients undergoing stem-cell transplantation","volume":"186","author":"Cortez","year":"2002","journal-title":"J Infect Dis"},{"key":"R101-20250827","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/1471-2334-14-99","article-title":"Case report: Passive transfer of hepatitis B antibodies from intravenous immunoglobulin","volume":"14","author":"Parker","year":"2014","journal-title":"BMC Infect Dis"}],"container-title":["Journal of Research in Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01222967-201621000-00037","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:21:49Z","timestamp":1787836909000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01222967-201621000-00037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":100,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.4103\/1735-1995.183992","relation":{},"ISSN":["1735-1995","1735-7136"],"issn-type":[{"value":"1735-1995","type":"print"},{"value":"1735-7136","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"2015-09-08","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-02-23","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}